Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome.

CP: Microbiology gut microbiota intestinal epithelial barrier irritable bowel syndrome low-FODMAP diet

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
15 11 2022
Historique:
received: 11 06 2022
revised: 25 07 2022
accepted: 21 10 2022
entrez: 17 11 2022
pubmed: 18 11 2022
medline: 22 11 2022
Statut: ppublish

Résumé

Changes in microbiome composition are associated with a wide array of human diseases, turning the human microbiota into an attractive target for therapeutic intervention. Yet, clinical translation of these findings requires the establishment of causative connections between specific microbial taxa and their functional impact on host tissues. Here, we infuse gut organ cultures with longitudinal microbiota samples collected from therapy-naive patients with irritable bowel syndrome (IBS) under a low-fermentable oligo-, di-, mono-saccharides and polyols (FODMAP) diet. We show that post-diet microbiota regulates intestinal expression of inflammatory and neuro-muscular gene sets. Specifically, we identify Bifidobacterium adolescentis as a diet-sensitive pathobiont that alters tight junction integrity and disrupts gut barrier functions. Collectively, we present a pathway discovery platform for mechanistic dissection and identification of functional diet-host-microbiota modules. Our data support the hypothesis that the gut microbiota mediates the beneficial effects of a low-FODMAP diet and reinforce the potential feasibility of microbiome-based therapies in IBS.

Identifiants

pubmed: 36384106
pii: S2211-1247(22)01528-5
doi: 10.1016/j.celrep.2022.111657
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111657

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Hadar Bootz-Maoz (H)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Ayelet Pearl (A)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Ehud Melzer (E)

Department of Gastroenterology and Liver Disease, Kaplan Medical Center, Rehovot, Israel; Hadassah Medical Center, the Hebrew University, Jerusalem, Israel.

Stephen Malnick (S)

Department of Internal Medicine, Kaplan Medical Center, Rehovot, Israel; Hadassah Medical Center, the Hebrew University, Jerusalem, Israel.

Efrat Sharon (E)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Yifat Bennet (Y)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Rotem Tsentsarevsky (R)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Shlomi Abuchatzera (S)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Sivan Amidror (S)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Elana Aretz (E)

Department of Gastroenterology and Liver Disease, Kaplan Medical Center, Rehovot, Israel.

Shalhevet Azriel (S)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Chen Gam Ze Letova (C)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Maria Naama (M)

Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Irit Shoval (I)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Orly Yaron (O)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Sarit Karako-Lampert (S)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel.

Shai Bel (S)

Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Nissan Yissachar (N)

The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan 5290002, Israel. Electronic address: nissan.yissachar@biu.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH